Avenue Therapeutics, Inc. Gains 35.96%
Mon, Feb 28, 2022 at 05:30 PM
Avenue Therapeutics, Inc. (ATXI:NASDAQ) shot up at $0.34, a gain of 36%. The stock appeared on our News Catalysts scanner on Wed, Feb 16, 2022 at 01:35 PM in the 'BIOTECH' category. From Fri, Feb 11, 2022, the stock recorded 22.22% Up Days and 30.00% Green Days
About Avenue Therapeutics, Inc. (ATXI:NASDAQ)
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl, or IV Tramadol, for the management of moderate to moderately severe postoperative pain.
Top 10 Gainers:
- Mullen Automotive Inc. (MULN:NASDAQ), 145.64%
- NeuroSense Therapeutics Ltd. (NRSN:NASDAQ), 68.83%
- Document Security Systems, Inc. (DSS:NYSEMKT), 47.24%
- China SXT Pharmaceuticals, Inc. (SXTC:NASDAQ), 45.33%
- Renewable Energy Group, Inc. (REGI:NASDAQ), 40.38%
- IntriCon Corporation (IIN:NASDAQ), 37.37%
- Avenue Therapeutics, Inc. (ATXI:NASDAQ), 35.96%
- Everbridge, Inc. (EVBG:NASDAQ), 29.11%
- First Horizon National Corporation (FHN:NYSE), 28.66%
- G Medical Innovations Holdings Ltd. (GMVD:NASDAQ), 27.91%